I-MAB SPONS.ADS/1 -0001 (0VY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, I-MAB SPONS.ADS/1 -0001 (0VY) has a cash flow conversion efficiency ratio of -0.063x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-14.60 Million ≈ $-17.06 Million USD) by net assets (€230.94 Million ≈ $269.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
I-MAB SPONS.ADS/1 -0001 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how I-MAB SPONS.ADS/1 -0001's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 0VY total debt and obligations for a breakdown of total debt and financial obligations.
I-MAB SPONS.ADS/1 -0001 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of I-MAB SPONS.ADS/1 -0001 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acsion Ltd
JSE:ACS
|
0.034x |
|
Excelliance MOS
TWO:5299
|
0.024x |
|
Aviat Networks Inc
NASDAQ:AVNW
|
-0.006x |
|
KIP Real Estate Investment Trust
KLSE:5280
|
0.021x |
|
Aurona Industries
TWO:8074
|
0.050x |
|
Value Added Technology Co. Ltd
KQ:043150
|
0.022x |
|
Pan Malaysia Holdings Bhd
KLSE:1287
|
-0.947x |
|
Kingstone Companies Inc
NASDAQ:KINS
|
0.076x |
Annual Cash Flow Conversion Efficiency for I-MAB SPONS.ADS/1 -0001 (2021–2025)
The table below shows the annual cash flow conversion efficiency of I-MAB SPONS.ADS/1 -0001 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see I-MAB SPONS.ADS/1 -0001 market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €230.94 Million ≈ $269.99 Million |
€-20.60 Million ≈ $-24.08 Million |
-0.089x | +65.94% |
| 2024-12-31 | €201.16 Million ≈ $235.18 Million |
€-52.67 Million ≈ $-61.58 Million |
-0.262x | +12.63% |
| 2023-12-31 | €242.58 Million ≈ $283.61 Million |
€-72.70 Million ≈ $-84.99 Million |
-0.300x | -154.92% |
| 2022-12-31 | €421.77 Million ≈ $493.09 Million |
€-49.58 Million ≈ $-57.97 Million |
-0.118x | +44.92% |
| 2021-12-31 | €715.33 Million ≈ $836.29 Million |
€-152.66 Million ≈ $-178.48 Million |
-0.213x | -- |
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which … Read more